HER2-NEGATIVE BREAST CANCER
Clinical trials for HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer combo trial halted early: what happened?
Disease control TerminatedThis early-stage trial tested a new drug, azenosertib, combined with two standard cancer drugs (carboplatin and pembrolizumab) in people with metastatic triple-negative breast cancer. The goal was to find a safe dose and see if the combination shrank tumors. Only 7 people took pa…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Filipa Lynce, MD • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising combo for rare breast cancer subtype hits early snag
Disease control TerminatedThis early-phase trial tested a combination of two drugs—infigratinib (a targeted therapy) and tamoxifen (a hormone therapy)—in people with a specific type of advanced breast cancer (hormone receptor-positive, HER2-negative, with FGFR gene changes). The goal was to find a safe do…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Radioactive 'Smart Bomb' for tumours tested in early trial
Disease control TerminatedThis early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New cancer drug BLU-222 tested in early trial – but study stopped early
Disease control TerminatedThis early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was te…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Cancer drug trial halted midway: what happened?
Disease control TerminatedThis study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC